APLS vs. ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, ASND, ROIV, and RVMD
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs.
Intra-Cellular Therapies (NASDAQ:ITCI) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends.
Intra-Cellular Therapies received 177 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.25% of users gave Apellis Pharmaceuticals an outperform vote while only 66.92% of users gave Intra-Cellular Therapies an outperform vote.
Intra-Cellular Therapies has higher revenue and earnings than Apellis Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Intra-Cellular Therapies has a net margin of -14.07% compared to Apellis Pharmaceuticals' net margin of -34.97%. Intra-Cellular Therapies' return on equity of -9.93% beat Apellis Pharmaceuticals' return on equity.
Intra-Cellular Therapies has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Intra-Cellular Therapies currently has a consensus price target of $103.62, suggesting a potential downside of 19.43%. Apellis Pharmaceuticals has a consensus price target of $46.71, suggesting a potential upside of 69.72%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Intra-Cellular Therapies.
In the previous week, Intra-Cellular Therapies had 7 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 15 mentions for Intra-Cellular Therapies and 8 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.52 beat Intra-Cellular Therapies' score of 0.45 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.
Summary
Intra-Cellular Therapies and Apellis Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 2/22/2025 by MarketBeat.com Staff
